Academic Journals Database
Disseminating quality controlled scientific knowledge

Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

Author(s): López-Cortés Luis | Viciana Pompeyo | Ruiz-Valderas Rosa | Pasquau Juan | Ruiz Josefa | Lozano Fernando | Merino Dolores | Vergara Antonio | Terrón Alberto | González Luis | Rivero Antonio | Muñoz-Sanz Agustin

Journal: AIDS Research and Therapy
ISSN 1742-6405

Volume: 7;
Issue: 1;
Start page: 5;
Date: 2010;
Original page

Abstract Background Ritonavir-boosted saquinavir (SQVr) is nowadays regarded as an alternative antiretroviral drug probably due to several drawbacks, such as its high pill burden, twice daily dosing and the requirement of 200 mg ritonavir when given at the current standard 1000/100 mg bid dosing. Several once-daily SQVr dosing schemes have been studied with the 200 mg SQV old formulations, trying to overcome some of these disadvantages. SQV 500 mg strength tablets became available at the end of 2005, thus facilitating a once-daily regimen with fewer pills, although there is very limited experience with this formulation yet. Methods Prospective, multicentre study in which efficacy, safety and pharmacokinetics of a regimen of once-daily SQVr 1500/100 mg plus 2 NRTIs were evaluated under routine clinical care conditions in either antiretroviral-naïve patients or in those with no previous history of antiretroviral treatments and/or genotypic resistance tests suggesting SQV resistance. Plasma SQV trough levels were measured by HPLV-UV. Results Five hundred and fourteen caucasian patients were included (47.2% coinfected with hepatitis C and/or B virus; 7.8% with cirrhosis). Efficacy at 52 weeks (plasma RNA-HIV
RPA Switzerland

Robotic Process Automation Switzerland


Tango Jona
Tangokurs Rapperswil-Jona